Results for Diabetes

Dr. Levine has an active laboratory research program that complements and extends his clinical studies. He has identified the molecular basis of several inherited disorders of mineral metabolism. His research interests extend to the molecular basis for embryological development of the parathyroid glands.

Dr. Willi's research focuses on therapeutics for type 1 and type 2 diabetes and he has performed a number of physiologic studies in the etiology and characterization of diabetes in children. His current studies include trials on the delay of progression of type 1 diabetes and a multicenter trial to examine the optimal therapeutics for type 2 diabetes in children.

Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.

Dr. Laskin's research focuses on the conduct of clinical investigations and translational studies designed to target mechanisms to prevent, treat, or slow the progression of chronic kidney disease in immunosuppressed patients, including children receiving a bone marrow or kidney transplant.

Dr. Argon investigates the unfolded protein response (UPR) , an essential signaling network that determines life or death of stressed cells and tissues. The IRE1 sensor of UPR responds to metabolic stress through four distinct activities and he focuses on determining which stress condition induces each activity and how they are integrated to enable the cells to cope with stress.

Dr. Pei's research aims to understand the molecular underpinnings of cardiac remodeling associated with cardiomyopathy and heart failure. He is particularly interested in two areas of cardiac remodeling: metabolic reprogramming, and secretion of heart-derived hormones to communicate with other organs.

Dr. Hill seeks to understand how the immune system contributes to the two most common chronic diseases of childhood: allergy and obesity. He uses clinical and epidemiological information to guide basic and translational research on the genetic, epigenetic, and immunologic basis of these important conditions.

Dr. McCormack investigates the intersection of neuroendocrinology and metabolism. Her translational research program involves two areas. The first involves studying those with genetic disorders, including primary mitochondrial diseases and Friedreich's ataxia, with characterized risk for diabetes mellitus. Second, Dr. McCormack focuses on brain disorders associated with excess weight gain, including brain tumor-related hypothalamic obesity syndrome and idiopathic intracranial hypertension.

Dr. Rubenstein's research focuses on basic and translational studies of novel means to improve outcomes in cystic fibrosis. He initially focused on correcting the dysfunction of mutant cystic fibrosis transmembrane conductance regulator (CFTR) proteins, which led him to study how molecular chaperones regulate the biogenesis and trafficking of CFTR and other proteins that are relevant to cystic fibrosis.

Bone disorders exact a considerable toll on human health in both children and adults. Dr. Long seeks to understand the fundamental mechanisms underlying both normal skeletal development and the pathophysiology of bone diseases. His current research includes studies of skeletal stem cells and progenitors, metabolic regulation of bone cells, and the integration of bone and whole-body metabolism.